Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
SJ

WKN: A2N9PC | ISIN: CNE100003FF7 | Ticker: 8SJ
Frankfurt
19.11.26 | 09:55
1,630 Euro
+1,24 % +0,020
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI JUNSHI BIOSCIENCES CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,6301,65016:39

Aktuelle News zur SHANGHAI JUNSHI BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiJUNSHI BIO Repurchases 170,400 Shrs on Wed for HKD2.3688 million1
DiJUNSHI BIO Repurchases 281,400 Shares for Approx. HKD4.01 million2
MoJUNSHI BIO Repurchases 303,000 Shares on Mon for HKD4.3M1
MoJUNSHI BIO (01877): NEXT DAY DISCLOSURE RETURN-
MoJUNSHI BIO Tuoyi Urothelial Carcinoma Indication Included in National Reimbursement Drug List1
MoJUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF TUOYI HAS BEEN INCLUDED IN THE NATIONAL REIMBURSEMENT DRUG LIST1
30.10.JUNSHI BIO First Patient Dosed in Phase III Trial of JS207 Combined With JS007 for Advanced Hepatocellular Carcinoma1
SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln
30.10.JUNSHI BIO 9M Loss Narrows to RMB149 Million1
29.10.JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON CASH MANAGEMENT BY USING TEMPORARILY IDLE ...3
29.10.JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2026 THIRD QUARTERLY REPORT3
29.10.JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2026 THIRD QUARTERLY ...1
29.10.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS207 IN COMBINATION WITH JS007 FOR ...1
29.10.Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma514SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the...
► Artikel lesen
29.10.Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma520SHANGHAI, China, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated...
► Artikel lesen
28.10.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB INJECTION (SUBCUTANEOUS INJECTION) FOR ...1
28.10.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - REGULAR APPROVAL FOR TORIPALIMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO ...2
28.10.Junshi Biosciences Announces Final Analysis Results of the Phase 3 NEOTORCH Study at ESMO Congress 2026570Perioperative toripalimab plus chemotherapy demonstrated significant and durable improvements in event-free survival and overall survival in patients with resectable stage II-III non-small cell lung...
► Artikel lesen
26.10.JUNSHI BIO JS203 Combined With Chemotherapy Phase III Clinical Study Completes First Patient Dosing3
24.10.Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma733SHANGHAI, China, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated...
► Artikel lesen
23.10.JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST PATIENT DOSING IN THE PHASE III CLINICAL TRIAL OF JS203 IN COMBINATION WITH CHEMOTHERAPY ...-
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1